Lupin has announced plans to invest $250 million (about ₹2,000 crore) over the next five years to set up a new greenfield manufacturing facility in Coral Springs, Florida. According to a regulatory filing, this state-of-the-art plant represents a significant step in Lupin’s expansion in the United States.
The upcoming 70,000-square-foot facility, situated on over five acres of acquired land, will be dedicated to producing more than 25 essential respiratory medicines. These will include lifesaving albuterol inhalers, which are crucial for children suffering from asthma and for service members both domestically and abroad.
Lupin stated that the project will substantially strengthen its domestic manufacturing base in the US and diversify its supply chain, anchoring the production of respiratory therapies within the country. The initiative is viewed as a proactive response to emerging trade tensions and policy changes, including new tariffs that may impact pharmaceutical operations.
“The investment demonstrates Lupin’s commitment to supply chain reliability and our ability to produce affordable treatments for patients,” said Christoph Funke, Chief Technology Officer at Lupin. Florida already serves as Lupin’s US headquarters, and this expansion further reinforces the company’s commitment to the American market. The US currently contributes about one-third of Lupin’s overall revenues.
